Ann Arbor, Michigan, March 3rd, 2016: TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, is presenting at the 29th International Conference on Antiviral Research (ICAR) April 17th - 21st at the Hilton La Jolla Torrey Pines hotel in La Jolla, CA.
Dr. Steven King will present on a "Genetically Optimized Banana Lectin for the Treatment of Influenza," and Dr. Eric Simon will present on an analytical method for characterization of BL-84, a genetically optimized therapeutic banana lectin. Furthermore, Dr. Shyamala Ganesan will present on the in vitro potency of nucleoside phosphonate analogues and Dr. Simon will present an LC-MS assay for measuring intracellular concentrations of USC-505, a nuceleoside phosphonate analogue.
Our collaborators Dr. William (Bill) Wold and Dr. Jennifer Moffat will present on the in vivo efficacy of nucleoside analogues in Syrian hamster and mice, respectively. Dr. Wold will present on the protection of immunocompromised Syrian hamsters against type 5 and 6 adenovirus and Dr. Moffat will present on the protection of mice against VZV, otherwise known as herpes zoster or shingles.
Abstracts are available here:
Genetically Optimized Banana Lectin for the Treatment of Influenza
Analytical Method Development for the Structural Characterization of BL-84, a Genetically Engineered, Recombinant Banana Lectin with Potent Antiviral Activity and Reduced Mitogenicity
Improved In Vitro Potency of Nucleoside Phosphonate Analogs against Different
Adenovirus Serotypes Using an Oral Prodrug Approach
Development of an LC-MS/MS Assay for Measurement of the Intracellular Concentrations of USC-505 (a Prodrug of Cidofovir) and its Metabolites
USC-087 and USC-505 Protect Immunosuppressed Syrian Hamsters against Lethal Intravenous Challenge with Human Type 5 and 6 Adenoviruses
Tyrosine Ester Prodrug of Cidofovir is Effective Against VZV in Mice
About TSRL, Inc:
TSRL, Inc. is a privately-held, anti-infectives pharmaceutical accelerator focused on the preclinical development of investigator-initiated drug therapy concepts. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Andrew Hertig, Business Development, 734-663-4233 x224, ahertig@tsrlinc.com.
